Novo Nordisk (CPSE:NOVO B) Secures UK Approval For Once-Daily Oral Wegovy Pill, Reshaping Obesity Treatment Access

Trouble Getting Weight Loss Drugs Covered by Insurance? Here’s What To Know

If your doctor prescribes a GLP-1 medication for weight loss but your insurance won’t cover it, you have options.

11% of Americans Are Currently Taking a GLP-1 Weight Loss Drug Like Wegovy

15 of Americans have ever taken the drugs, up from 6 in 2024.

Health Canada approves weight-loss drug for sleep apnea in patients with obesity

Health Canada has approved weight-loss drug Zepbound for treating obstructive sleep apnea in adults with obesity. The department confirmed that the authorization granted on June 11 makes Zepbound the only GLP-1 drug in Canada approved for the sleep disorder that causes people to stop breathing temporarily because their upper airway is blocked. That blockage can [] The post Health Canada approves weight-loss drug for sleep apnea in patients with obesity appeared first on CityNews Montreal.

Mike Nesbitt to role out weight loss medication across Northern Ireland with support from Mounjaro maker Eli Lilly

​​A new £5 million Regional Obesity Management Service (ROMS) is to make weight loss medication available to adults across Northern Ireland.

Canada approves 1st generic semaglutide shot for weight loss

It's the third generic semaglutide product approved by the department, though the first two were authorized for the treatment of Type 2 diabetes in adults.

Medicare Launches GLP-1 Bridge Program Covering Novo Nordisk (CPH: NOVO-B) And Eli Lilly (NYSE: LLY) Weight-Loss Drugs

Medicare is launching a temporary bridge program that will cover select GLP-1 weight-loss medications from two of the pharmaceutical industry’s largest players. The program will extend coverage to Novo Nordisk’s (CPH: NOVO-B) Wegovy, both in injection and tablet form, marking a significant shift in how the federal health program approaches obesity treatment. Eli Lilly’s (NYSE: [] The post Medicare Launches GLP-1 Bridge Program Covering Novo Nordisk (CPH: NOVO-B) And Eli Lilly (NYSE: LLY) Weight-Loss Drugs appeared first on Foreign Policy Journal.

A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss

Vivani Medical is developing an implant of semaglutide, the active ingredient in Novo Nordisk's obesity injection Wegovy and diabetes counterpart Ozempic.

Medicare patients can get GLP-1s as of July 1

Medicare beneficiaries for the first time will be eligible for coverage of breakthrough GLP-1 weight-loss medications after years of struggling to get the drugs to more seniors. Starting July 1, eligible patients can get GLP-1s to treat obesity for just 50 per month as part of a test program for Medicare, the social safety net []

MassHealth will stop covering weight-loss drugs next week

The change will leave an estimated 22,000 MassHealth members on the hook to pay out of pocket for the pricy GLP-1s and other anti-obesity drugs. The post MassHealth will stop covering weight-loss drugs next week appeared first on Boston.com.

I've been on GLP-1s for 16 months – here's why I won't be swapping to the new weight loss pill

Weight loss drug Wegovy is finally available in pill form, making it more accessible to people who want the benefits of GLP-1s – but is it worth making the swap?

US FDA declines to approve Sobi’s therapy for uncontrolled gout

US FDA declines to approve Sobi’s therapy for uncontrolled gout

Medicare (temporarily) covers GLP-1s starting tomorrow

Click in for more news from The Hill {beacon} Healthcare Health Care The Big Story Temporary Medicare GLP-1 coverage begins tomorrow The Trump administration’s temporary program to cover GLP-1 medications for obesity starts tomorrow and runs through 2027, but we still don’t know for sure how much it will cost taxpayers. © Adobe Stock Medicare is prohibited by law from covering weight-loss drugs but the...

Business : Vivani, Novo Nordisk Sign Agreement To Evaluate Weight Management Implant

KUALA LUMPUR, July 8 (Bernama) -- Vivani Medical Inc (Vivani), a biopharmaceutical company developing ultra long-acting drug implants, has signed an agreement with Novo Nordisk to evaluate its semaglutide drug implant, NPM-139, for chronic weight management.

Alembic Pharmaceuticals gets USFDA nod for generic acne treatment gel

The approval by the USFDA is for the abbreviated new drug application (ANDA) of Dapsone gel, 5 per cent

Healthcare's Quiet Comeback: Innovation, Obesity Drugs And New Opportunities

Healthcare's Quiet Comeback: Innovation, Obesity Drugs And New Opportunities

One 79-year-old Patient Given Unapproved Powerful Obesity Drug

Speculation swirled around a report that a single patient -- a 79-year-old man -- was given access to a powerful new obesity drug that's still awaiting federal approval.

Trouble getting weight loss drugs covered by insurance? Here's what to know

What to do if your insurance denies your obesity drug.

A New FDA-Approved Oral Weight Loss Pill Requires No Fasting: What Makes Foundayo Different from Other GLP-1 Drugs

FDA approved Foundayo (orforglipron) on April 1, 2026 — the only oral GLP-1 pill for weight loss you can take any time of day without fasting. Average weight loss: 12.4. Here's the breakdown.

A patient got the weight loss medication retatrutide before FDA approval. How does that work?

A primer on retatrutide and compassionate use

Medicare is now covering some GLP-1 weight loss drugs for $50. Here’s what to know

The federal government has launched a new program to make GLP-1 weight loss drugs more affordable for older Americans

Canada approves the first generic semaglutide injection for weight loss

Health Canada has approved the first generic semaglutide injection for weight loss.

Medicare is now covering some GLP-1 weight loss drugs for $50. Here’s what to know

NEW YORK (AP) — Popular — and expensive — GLP-1 weight loss drugs just got a lot cheaper for many older Americans.

Substack 4: Nutrition Researchers Say It’s the Doctors Who Are Fooling Themselves – Are They?

The very controversial history surrounding dietary therapy for obesity and diabetes comes down to one consistent and very obvious conflict. Physicians, like the UK’s David Unwin in his recent article, insist that they know better how to successfully treat their patients than the academic nutritionists and epidemiologists in their Ivy Towers. The physicians have argued...Read More »

Comprehensive guide on weight loss using GLP-1 medications: Here’s a detailed list!

Glucagon-like peptide-1 (GLP-1) therapies have offered clinically proven weight-loss and metabolic benefits. We know that obesity is a relapsing and chronic ailment that has affected more than 1 billion individuals across the world. Hence, knowing what to do makes all the difference. What are GLP-1 agonists in brief? These are classes of medicines that are usually...

Wegovy weight loss pill now available in UK - here's what you need to know

The once-a-day pill, from the makers of the Wegovy weight-loss jab, can now be bought privately in UK pharmacies.

GC Wellbeing secures rights to obesity treatment RZL-012 for Korean market

GC Wellbeing secures rights to obesity treatment RZL-012 for Korean market

Contributor: Mental health care isn't ready for psychedelic side effects

Accelerated FDA approval will invite recklessness. But don't block these important medications. Take steps to prepare.

Study: Combined medication and lifestyle changes work best for children with obesity

Study: Combined medication and lifestyle changes work best for children with obesity

Replacing sugary drinks with water, tea or coffee tied to lower diabetes risk, studies show

(NaturalNews) Replacing one daily sugary drink with water, coffee or unsweetened tea can lower Type 2 diabetes risk by up to 10. For adults with Type 2 diab...

Why the secret to losing weight could be a simple tweak to your prescription. If you take medication every day, here's what you must ask your GP

Why the secret to losing weight could be a simple tweak to your prescription. If you take medication every day, here's what you must ask your GP

Obesity: Free medication program ends as Health Ministry seeks two-month extension

If the extension is not approved, the disruption will affect only July and August, as the entire Prevent program is expected to resume with national funding from September, the Prime Minister announced at the ygeiamou.gr health conference The post Obesity: Free medication program ends as Health Ministry seeks two-month extension appeared first on ProtoThema English.

The weightloss pill that could change the game for Aussies | 9 News Australia

Doctors say a pill version of the weightloss injectable Wegovy will make treatment more accessible for Australians. It's just been launched in the UK, but the green light is yet to be given by Australia's medical watchdog for two oral GLP-1 medications. #9News | Subscribe and 🔔: http://9Soci.al/KM6e50GjSK9 | Get more breaking news at nine.com.au FOLLOW 9News Australia ► Facebook: https://www.facebook.com/9News/ ► X: https://twitter.com/9NewsAUS ► Instagram: https://www.instagram.com/9news/ ► TikTok: https://www.tiktok.com/@9news Join 9News for the latest in news and events that affect you in your local city, as well as news from across Australia and the world. #BREAKINGNEWS #9NEWS #AUSTRALIA

Eli Lilly’s Unapproved Weight-Loss Drug Is Now Sold at Brooklyn Corner Stores for $95

A CBS News reporter purchased Eli Lilly's experimental weight-loss drug retatrutide at a Brooklyn convenience store for 95 with no prescription as toxicity reports rise and the FDA warns such products are of unknown quality and potentially harmful. The drug is currently in clinical trials and has never received regulatory approval.

High Court rules in favour of Novo Nordisk South Africa, halting illicit compounding with immediate effect

Legal win for Novo Nordisk South Africa: Pretoria High Court orders iDexis to halt illicit compounding of unregistered semaglutide with immediate effect High Court confirms that only registered APIs, dispensed on prescription, may be used in compounding Ruling reinforces SAHPRA and SAPC oversight and protects patients from unsafe GLP-1 medicines Johannesburg, South Africa, 06 July []

PopInfo Weekly: Predictions, prescriptions, and payouts

Independent accountability journalism.

Wegovy weight loss pills are now available in the UK — and 70,000 Brits are queueing for them

There are two slight problems.

White House Cornered on Identity of Patient, 79, Given Special Weight Loss Drug

Photo Illustration by Elizabeth Brockway/The Daily Beast/GettyA 79-year-old man was given special access to an unreleased Eli Lilly obesity drug in April that was unavailable to the public. At first, those with knowledge of the patient’s identity would not directly deny that the man was President Donald Trump, who turned 80 earlier this month.Stat News reported Tuesday that the drug, called retatrutide, drew the interest of several top health officials, suggesting that the person who obtained it was high up the chain of command.Read more at The Daily Beast.

How do you sell weight loss drugs without advertising them?

CNN's Anna Cooban explores how companies like Novo Nordisk navigate advertising restrictions to promote weight loss drugs outside the UK.

Medicare offers access to popular obesity drugs for $50 a month

Medicare is offering beneficiaries access to popular obesity drugs for a 50 monthly copay. Patients have to meet certain criteria to qualify. It's a temporary measure that runs through 2027.